EUVIMEDEUVIMED entdecken
Crossref

Development of Granzyme B-targeted Smart Positron Emission Tomography Probes for Monitoring Tumor Early Response to Immunotherapy

Jiayu Fu, Hongjie Xi, Shuyue Cai, Ying Peng, Qingzhu Liu, Ling Qiu, Jianguo Lin iD

ACS Nano · 2024

DOI: 10.1021/acsnano.4c01157 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2024. Verfasst von Jiayu Fu und 6 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu 21…. Hauptthemen laut MEDLINE: Granzymes, Positron-Emission Tomography, Immunotherapy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Commission of Health, Jiangsu Provincial Medical Key Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Granzyme B is an immune-related biomarker that closely correlates with cytotoxic T lymphocytes (CTLs), and hence detecting the expression level of granzyme B can provide a dependable scheme for clinical immune response assessment. In this study, two positron emission tomography (PET) probes [18F]SF-M-14 and [18F]SF-H-14 targeting granzyme B are designed based on the intramolecular cyclization scaffold SF. [18F]SF-M-14 and [18F]SF-H-14 can respond to granzyme B and glutathione (GSH) to conduct intramolecular cyclization and self-assemble into nanoaggregates to enhance the retention of probe at the target site. Both probes are prepared with high radiochemical purity (>98%) and high stability in PBS and mouse serum. In 4T1 cells cocultured with T lymphocytes, [18F]SF-M-14 and [18F]SF-H-14 reach the maximum uptake of 6.71 ± 0.29 and 3.47 ± 0.09% ID/mg at 0.5 h, respectively, but they remain below 1.95 ± 0.22 and 1.47 ± 0.21% ID/mg in 4T1 cells without coculture of T lymphocytes. In vivo PET imaging shows that the tumor uptake in 4T1-tumor-bearing mice after immunotherapy is significantly higher (3.5 times) than that in the untreated group. The maximum tumor uptake of [18F]SF-M-14 and [18F]SF-H-14 in the mice treated with BEC was 4.08 ± 0.16 and 3.43 ± 0.12% ID/g, respectively, while that in the untreated mice was 1.04 ± 0.79 and 1.41 ± 0.11% ID/g, respectively. These results indicate that both probes have great potential in the early evaluation of clinical immunotherapy efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GranzymesPositron-Emission TomographyImmunotherapyAnimalsMiceFemaleMice, Inbred BALB CCell Line, TumorRadiopharmaceuticalsFluorine RadioisotopesHumans

Stichwörter der Autor:innen

granzyme Bimmunotherapymolecular probepositron emission tomographyresponse evaluation

Substanzen

GranzymesRadiopharmaceuticalsFluorine Radioisotopes

Autor:innen und Institutionen

  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu 214063, China.
  • Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.

ORCID-Profile: Jianguo Lin

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Commission of Health
  • Jiangsu Provincial Medical Key Laboratory
  • Wuxi Municipality

Zitieren

APA

Fu, J., Xi, H., Cai, S., Peng, Y., Liu, Q., Qiu, L., & Lin, J. (2024). Development of Granzyme B-targeted Smart Positron Emission Tomography Probes for Monitoring Tumor Early Response to Immunotherapy. ACS Nano. https://doi.org/10.1021/acsnano.4c01157

Vancouver

Fu J, Xi H, Cai S, Peng Y, Liu Q, Qiu L, et al. Development of Granzyme B-targeted Smart Positron Emission Tomography Probes for Monitoring Tumor Early Response to Immunotherapy. ACS Nano. 2024. doi:10.1021/acsnano.4c01157

BibTeX
@article{Fu2024,
  author = {Fu, Jiayu and Xi, Hongjie and Cai, Shuyue and Peng, Ying and Liu, Qingzhu and Qiu, Ling and Lin, Jianguo},
  title = {Development of Granzyme B-targeted Smart Positron Emission Tomography Probes for Monitoring Tumor Early Response to Immunotherapy},
  journal = {ACS Nano},
  year = {2024},
  doi = {10.1021/acsnano.4c01157}
}
Kostenlos starten →